TDC
CDTX

Thompson Davis & Co’s Cidara Therapeutics CDTX Stock Holding History

Thompson Davis & Co’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$9K Buy
+100
New +$8.82K 0.02% 465

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Thompson Davis & Co's CDTX Position: Q3 2018 in Review

Thompson Davis & Co opened a new position in Cidara Therapeutics (CDTX) in Q3 2018: 100 shares worth $9K. The stake represents 0.02% of the portfolio and ranks #465 among its holdings.

59 funds tracked by Wall St. Rank hold CDTX as of Q3 2018.

  • Thompson Davis & Co held 100 shares of Cidara Therapeutics worth $9K as of Q3 2018.
  • Cidara Therapeutics was a new Thompson Davis & Co position in Q3 2018.
  • Cidara Therapeutics made up 0.02% of Thompson Davis & Co's portfolio in Q3 2018, its #465 holding.
  • 59 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.